| Kaitlin C Gudger, CPNP-PC | |
|
1005 Commercial Ln Ste 220, Suffolk, VA 23434 | |
| (757) 668-2600 | |
| Not Available |
| Full Name | Kaitlin C Gudger |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Pediatrics |
| Location | 1005 Commercial Ln Ste 220, Suffolk, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194214924 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 00001231765 (Virginia) | Secondary |
| 363LP0200X | Nurse Practitioner - Pediatrics | 0024176410 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kaitlin C Gudger, CPNP-PC Po Box 2114, Suffolk, VA 23432-0114 Ph: (757) 618-3678 | Kaitlin C Gudger, CPNP-PC 1005 Commercial Ln Ste 220, Suffolk, VA 23434 Ph: (757) 668-2600 |
News Archive
Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement.
Revive, a national public relations firm specializing in Health Care and Healthy Living, today released the results of its fourth annual National Payor Survey of hospital executives. The only one of its kind in the country, the survey targeted hospital leaders in the industry who negotiate managed care contracts with national health insurance companies - CEOs, CFOs, and directors of managed care. Participants represent 24% of hospitals in the U.S., up from 18% last year.
CURE Media Group, the nation's leading digital and print media enterprise focused on cancer patients and survivors of cancer, welcomes CancerCare to its Strategic Alliance Partnership Program.
Researchers and caregivers have noted that excessive daytime napping can develop long before the memory problems associated with Alzheimer's disease begin to unfold.
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and meet investors at a number of leading forthcoming investor conferences.
› Verified 8 days ago